BioCentury
ARTICLE | Clinical News

CEGE Phase I/II prostate cancer data

October 23, 2001 7:00 AM UTC

Cell Genesys (CEGE) said its CG7870 (formerly CV787) oncolytic virus against prostate cancer cells had antitumor activity after a single intravenous injection in patients with advanced hormone refract...